{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:15:34Z","timestamp":1789668934997,"version":"4.0.1"},"reference-count":30,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,27]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The concept of restoring hemostasis by down-tuning anticoagulant pathways holds the promise of treating all forms of hemophilia. Here, we report preclinical efficacy and safety data for SerpinPC, a covalent inhibitor of activated protein C (APC). APC is a serine protease that degrades the enzyme complex that produces thrombin, and its inhibition allows for more thrombin to be produced during the initiation stage of hemostasis. In a hemophilia A (HA) mouse tail clip model, SerpinPC treatment reduced blood loss in a dose- and time-dependent manner to levels comparable with wild-type (WT) mice. SerpinPC was able to treat active bleeds in HA mice and prevented spontaneous internal bleeding when given prophylactically. SerpinPC treatment was not associated with an increased inflammatory response and was well tolerated at high doses in WT animals. SerpinPC is currently being evaluated in individuals with severe hemophilia.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015201","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T22:57:16Z","timestamp":1741993036000},"page":"2402-2409","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["The preclinical profile of SerpinPC: a potential new treatment for hemophilia"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0076-7204","authenticated-orcid":false,"given":"James A.","family":"Huntington","sequence":"first","affiliation":[{"name":"1Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom"},{"name":"2ApcinteX Ltd, Altrincham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Reckless","sequence":"additional","affiliation":[{"name":"3RxCelerate Ltd, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4210-6677","authenticated-orcid":false,"given":"St\u00e9phanie G. I.","family":"Polderdijk","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hextall","sequence":"additional","affiliation":[{"name":"2ApcinteX Ltd, Altrincham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor P.","family":"Baglin","sequence":"additional","affiliation":[{"name":"2ApcinteX Ltd, Altrincham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"issue":"6","key":"2025052708570198700_bib1","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1055\/s-0037-1615947","article-title":"A cell-based model of hemostasis","volume":"85","author":"Hoffman","year":"2001","journal-title":"Thromb Haemost"},{"issue":"7","key":"2025052708570198700_bib2","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1046\/j.1538-7836.2003.00298.x","article-title":"What is all that thrombin for?","volume":"1","author":"Mann","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"suppl 1","key":"2025052708570198700_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2006-939550","article-title":"An overview of the structure and function of thrombin","volume":"32","author":"Davie","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"2025052708570198700_bib4","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2741\/3926","article-title":"Tissue factor pathway inhibitor: structure-function","volume":"17","author":"Broze","year":"2012","journal-title":"Front Biosci"},{"issue":"11","key":"2025052708570198700_bib5","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.biochi.2010.05.011","article-title":"Molecular mechanisms of antithrombin\u2013heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors","volume":"92","author":"Olson","year":"2010","journal-title":"Biochimie"},{"issue":"7","key":"2025052708570198700_bib6","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1161\/01.ATV.0000168421.13467.82","article-title":"Regulation of blood coagulation by the protein C anticoagulant pathway","volume":"25","author":"Dahlb\u00e4ck","year":"2005","journal-title":"Arter., Thromb Vasc Biol"},{"issue":"5","key":"2025052708570198700_bib7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood-2018-08-872291","article-title":"New therapies for hemophilia","volume":"133","author":"Weyand","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2025052708570198700_bib8","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3390\/ph15101183","article-title":"Updates on novel non-replacement drugs for hemophilia","volume":"15","author":"Gualtierotti","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"5","key":"2025052708570198700_bib9","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/MOH.0000000000000364","article-title":"Targeting activated protein C to treat hemophilia","volume":"24","author":"Polderdijk","year":"2017","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"2025052708570198700_bib10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/blood-2016-05-718635","article-title":"Design and characterization of an APC-specific serpin for the treatment of hemophilia","volume":"129","author":"Polderdijk","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2025052708570198700_bib11","doi-asserted-by":"crossref","first-page":"e0154857","DOI":"10.1371\/journal.pone.0154857","article-title":"Shortened lifespan and lethal hemorrhage in a hemophilia A mouse model","volume":"11","author":"Staber","year":"2016","journal-title":"PLoS ONE"},{"issue":"1","key":"2025052708570198700_bib12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00281-011-0284-6","article-title":"Protein C anticoagulant system\u2014anti-inflammatory effects","volume":"34","author":"Esmon","year":"2012","journal-title":"Semin Immunopathol"},{"issue":"5","key":"2025052708570198700_bib13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1538-7836.2009.03333.x","article-title":"Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride-induced septic shock","volume":"7","author":"Xu","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2025052708570198700_bib14","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/jth.14380","article-title":"Administration of recombinant FVIIa (rFVIIa) to concizumab- dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits","volume":"17","author":"Lauritzen","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2025052708570198700_bib15","doi-asserted-by":"crossref","first-page":"e0178544","DOI":"10.1371\/journal.pone.0178544","article-title":"Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay","volume":"12","author":"Schultz","year":"2017","journal-title":"PLoS ONE"},{"issue":"3","key":"2025052708570198700_bib16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/adc.60.3.261","article-title":"Reference ranges for serum alpha 1 antitrypsin","volume":"60","author":"Ward","year":"1985","journal-title":"Arch Dis Child"},{"issue":"6","key":"2025052708570198700_bib17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0952-7915(92)90049-K","article-title":"B-cell tolerance","volume":"4","author":"Goodnow","year":"1992","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"2025052708570198700_bib18","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.4049\/jimmunol.170.6.3007","article-title":"A threshold for central T cell tolerance to an inducible serum protein","volume":"170","author":"Haribhai","year":"2003","journal-title":"J Immunol"},{"issue":"10274","key":"2025052708570198700_bib19","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0140-6736(20)32722-7","article-title":"The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing","volume":"397","author":"Mancuso","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"2025052708570198700_bib20","doi-asserted-by":"crossref","first-page":"e28934","DOI":"10.1002\/pbc.28934","article-title":"Novel treatments for hemophilia through rebalancing of the coagulation cascade","volume":"68","author":"Zhao","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2025052708570198700_bib21","doi-asserted-by":"crossref","first-page":"e911","DOI":"10.1097\/HS9.0000000000000911","article-title":"Nonfactor therapies for hemophilia","volume":"7","author":"Young","year":"2023","journal-title":"HemaSphere"},{"issue":"5","key":"2025052708570198700_bib22","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/hae.14595","article-title":"Befovacimab, an anti-tissue factor pathway inhibitor antibody: early termination of the multiple-dose, dose-escalating phase 2 study due to thrombosis","volume":"28","author":"Mancuso","year":"2022","journal-title":"Haemophilia"},{"issue":"4","key":"2025052708570198700_bib23","doi-asserted-by":"crossref","first-page":"100179","DOI":"10.1016\/j.rpth.2023.100179","article-title":"Antithrombin lowering in hemophilia: a closer look at fitusiran","volume":"7","author":"Young","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"6806","key":"2025052708570198700_bib24","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/35038119","article-title":"Structure of a serpin\u2013protease complex shows inhibition by deformation","volume":"407","author":"Huntington","year":"2000","journal-title":"Nature"},{"issue":"19","key":"2025052708570198700_bib25","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1182\/blood-2015-02-355974","article-title":"Activated protein C: biased for translation","volume":"125","author":"Griffin","year":"2015","journal-title":"Blood"},{"issue":"1-2","key":"2025052708570198700_bib26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jim.2006.05.004","article-title":"A novel ELISA for mouse activated protein C in plasma","volume":"314","author":"Fern\u00e1ndez","year":"2006","journal-title":"J Immunol Methods"},{"issue":"11","key":"2025052708570198700_bib27","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1111\/jth.14272","article-title":"A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A","volume":"16","author":"Eichler","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2025052708570198700_bib28","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s40265-018-0922-6","article-title":"Inhibition of tissue factor pathway inhibitor (TFPI) as a treatment for haemophilia: rationale with focus on concizumab [published correction appears in Drugs. 2018;78(9):891]","volume":"78","author":"Chowdary","year":"2018","journal-title":"Drugs"},{"issue":"9","key":"2025052708570198700_bib29","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/jth.14207","article-title":"A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers","volume":"16","author":"Cardinal","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2025052708570198700_bib30","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"J Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/10\/2402\/2374419\/blooda_adv-2024-015201-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/10\/2402\/2374419\/blooda_adv-2024-015201-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T12:57:11Z","timestamp":1748350631000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/10\/2402\/536050\/The-preclinical-profile-of-SerpinPC-a-potential"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,5,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015201","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,27]]},"published":{"date-parts":[[2025,5,14]]}}}